Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewThalidomide-4-hydroxyacetate
Description: Carboxylic acid-functionalized Thalidomide; cereblon ligand for PROTACs
Chemical Name: 2-[[2-(2,6-Dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]acetic acid
Purity: ≥98% (HPLC)
Biological Activity for Thalidomide-4-hydroxyacetate
Thalidomide-4-hydroxyacetate is a derivative of Thalidomide (Cat.No. 0652), commonly used as a precursor to PROTAC® that hijacks cereblon as the E3 ubiquitin ligase component. Supplied with a carboxylic acid functional handle at a position known not to significantly affect binding to cereblon, for ready conjugation to a linker/target protein ligand.
Thalidomide-4-hydroxyacetate has been recently renamed. The previous name for this product was TC E3 5031.
Please contact us for SD files of our available Degrader Building Blocks.
PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
Require a different derivative? Get in touch.
Usage Guidelines for Thalidomide-4-hydroxyacetate
This product is provided for use in onward chemistry. Suitable solvents can be used.
Technical Data for Thalidomide-4-hydroxyacetate
| M. Wt | 332.26 |
| Formula | C15H12N2O7 |
| Storage | Store at RT |
| Purity | ≥98% (HPLC) |
| CAS Number | 1061605-21-7 |
| PubChem ID | 25015436 |
| InChI Key | ZVWIXIGBWIEDFO-UHFFFAOYSA-N |
| Smiles | O=C(N1C(CC2)C(NC2=O)=O)C3=C(C1=O)C(OCC(O)=O)=CC=C3 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for Thalidomide-4-hydroxyacetate
References for Thalidomide-4-hydroxyacetate
References are publications that support the biological activity of the product.
Lohbeck and Miller (2016) Practical synthesis of a phthalimide-based cereblon ligand to enable PROTAC development. Bioorg.Med.Chem.Lett. 26 5260 PMID: 27687673
If you know of a relevant reference for Thalidomide-4-hydroxyacetate, please let us know.
View Related Products by Target
Keywords: Thalidomide-4-hydroxyacetate, Thalidomide-4-hydroxyacetate supplier, PROTACs, thalidomide, PROteolysis, TArgeting, Chimeras, cereblon, E3, ligase, ligand, 3, TCE35031, 2434840-81-8, 2357105-38-3, Functionalized, Ligase, Ligands, 6466, Tocris Bioscience
Citations for Thalidomide-4-hydroxyacetate
Citations are publications that use Tocris products.
Currently there are no citations for Thalidomide-4-hydroxyacetate. Do you know of a great paper that uses Thalidomide-4-hydroxyacetate from Tocris? Please let us know.
Reviews for Thalidomide-4-hydroxyacetate
There are currently no reviews for this product. Be the first to review Thalidomide-4-hydroxyacetate and earn rewards!
Have you used Thalidomide-4-hydroxyacetate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Targeted Protein Degradation Poster
Degraders (e.g. PROTACs) are bifunctional small molecules, that harness the Ubiquitin Proteasome System (UPS) to selectively degrade target proteins within cells. They consist of three covalently linked components: an E3 ubiquitin ligase ligand, a linker and a ligand for the target protein of interest. Authored in-house, this poster outlines the generation of a toolbox of building blocks for the development of Degraders. The characteristics and selection of each of these components are discussed. Presented at EFMC 2018, Ljubljana, Slovenia